AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38695396 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 38695479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib + pembrolizumab + chemotherapy
Number of subjects: 0
Study 38695479 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab + chemotherapy
Number of subjects: 0
Study 38695527 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten dose-titration regimen guided by echocardiographic measures
Number of subjects: 5
Study 38695527 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated regimen with optimal benefit-risk profile
Number of subjects: 5
Study 38695604 — intervention group
Group type: EXPERIMENTAL
Intervention: SQZ-PBMC-HPV (administered as monotherapy every 3 weeks)
Number of subjects: 18
Study 38695613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant use
Number of subjects: 2376
Study 38695743 — intervention group
Group type: EXPERIMENTAL
Intervention: Predisposed HFpEF
Number of subjects: 151
Study 38695743 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 151
Study 38695743 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study 38696027 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 1683
Study 38696027 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 1683
Study 38696027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1683
Study 38696027 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (both dosages)
Number of subjects: 1683
Study 38696034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study 38696034 — intervention group
Group type: COMPARATOR
Intervention: Tumor necrosis factor inhibitors (TNFi)
Number of subjects: 0
Study 38696122 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat (starting dose: 2 mg bid; maximum: 30 mg bid)
Number of subjects: 137
Study 38696122 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 137
Study 38696203 — intervention group
Group type: COMPARATOR
Intervention: Combined Nicotine Replacement Therapy (CNRT)
Number of subjects: 490
Study 38696203 — intervention group
Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 490
Study 38696203 — intervention group
Group type: COMPARATOR
Intervention: Combined Nicotine Replacement Therapy (CNRT) and Varenicline
Number of subjects: 490
Study 38696220 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Number of subjects: 0
Study 38696220 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38696221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (R,S)-Ketamine
Number of subjects: 0
Study 38696221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38696284 — intervention group
Group type: EXPERIMENTAL
Intervention: XC001
Number of subjects: 32
Study 38696406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Care Program with Virtual Reality (MBHC-VR)
Number of subjects: 0
Study 38696406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Care Program (MBHC)
Number of subjects: 0
Study 38696406 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 38696428 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual AFOs
Number of subjects: 58
Study 38696428 — intervention group
Group type: COMPARATOR
Intervention: Emulated AFOs
Number of subjects: 58
Study 38696657 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory training, details on dosage and duration not available
Number of subjects: 0
Study 38696657 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 38696672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Rapid Lispro Insulin with Control-IQ Technology
Number of subjects: 0
Study 38696675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy focal CF catheter with RF and pulsed field ablation (PFA)
Number of subjects: 149
Study 38696701 — intervention group
Group type: EXPERIMENTAL
Intervention: Male cohort (S-ICD recipients)
Number of subjects: 374
Study 38696701 — intervention group
Group type: COMPARATOR
Intervention: Female cohort (S-ICD recipients)
Number of subjects: 374
Study 38696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medically tailored meals, groceries, and nutritional education
Number of subjects: 191
Study 38696724 — intervention group
Group type: COMPARATOR
Intervention: POH 'standard of care' food services
Number of subjects: 191
Study 38697155 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5·4 mg/kg intravenously once every 21 days)
Number of subjects: 608
Study 38697155 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (capecitabine, lapatinib, or trastuzumab)
Number of subjects: 608
Study 38697155 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 608
Study 38697155 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 608
Study 38697156 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg) plus gemcitabine and cisplatin
Number of subjects: 685
Study 38697156 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine and cisplatin
Number of subjects: 685
Study 38697182 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCL therapy (MiniMed 780G)
Number of subjects: 95
Study 38697182 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 95
Study 38697184 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide (3.0 mg, subcutaneously once a day for 16 weeks)
Number of subjects: 18
Study 38697184 — intervention group
Group type: COMPARATOR
Intervention: Historic control rate
Number of subjects: 18
Study 38697216 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform Multidrug Therapy (U-MDT) for 6 months
Number of subjects: 613
Study 38697216 — intervention group
Group type: COMPARATOR
Intervention: Regular Multidrug Therapy (R-MDT) for 12 months
Number of subjects: 613
Study 38697216 — intervention group
Group type: COMPARATOR
Intervention: Comparison of U-MDT and R-MDT
Number of subjects: 613
Study 38697235 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy only
Number of subjects: 738
Study 38697235 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice of colonoscopy or FIT
Number of subjects: 738
Study 38697235 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT only
Number of subjects: 738
Study 38697286 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 426
Study 38697286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 38697618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg by mouth twice daily and capecitabine 1000 mg/m2 by mouth twice daily
Number of subjects: 42
Study 38697618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib and capecitabine
Number of subjects: 42
Study 38697677 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of once-weekly online Singing for Lung Health (SLH) sessions
Number of subjects: 115
Study 38697677 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 115
Study 38697766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home treatment
Number of subjects: 849
Study 38697821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy using indocyanine green
Number of subjects: 100
Study 38697873 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuranolone
Number of subjects: 0
Study 38698170 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus Binimetinib
Number of subjects: 0
Study 38698175 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 245
Study 38698175 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 245
Study 38698315 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused psychotherapy
Number of subjects: 0
Study 38698315 — intervention group
Group type: COMPARATOR
Intervention: Non-trauma-focused psychotherapy
Number of subjects: 0
Study 38698355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD) for 5 days per month for 12 months
Number of subjects: 100
Study 38698355 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 100
Study 38698396 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 ml iPAAG injection
Number of subjects: 49
Study 38698433 — intervention group
Group type: EXPERIMENTAL
Intervention: Active spinal manual therapy
Number of subjects: 60
Study 38698433 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control spinal manual therapy
Number of subjects: 60
Study 38698442 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental enteral protein (1.2 g/kg/day) added to standard enteral nutrition to achieve a high amount of enteral protein (2-2.4 g/kg/day)
Number of subjects: 2502
Study 38698442 — intervention group
Group type: COMPARATOR
Intervention: No supplemental enteral protein to achieve a moderate amount of enteral protein (0.8-1.2 g/kg/day)
Number of subjects: 2502
Study 38698442 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental enteral protein (1.2 g/kg/day)
Number of subjects: 2502
Study 38698442 — intervention group
Group type: COMPARATOR
Intervention: No supplemental enteral protein
Number of subjects: 2502
Study 38698471 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused lung ultrasonography (FLUS) performed in addition to usual care
Number of subjects: 0
Study 38698471 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38698497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension training courses
Number of subjects: 124
Study 38698497 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys measuring adaptive reserve, evidence-based practice attitudes, and implementation leadership
Number of subjects: 124
Study 38698497 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews assessing facilitators and barriers to hypertension care delivery
Number of subjects: 124
Study 38698639 — intervention group
Group type: EXPERIMENTAL
Intervention: DopaFuse therapy (continuous delivery of levodopa/carbidopa)
Number of subjects: 16
Study 38698639 — intervention group
Group type: COMPARATOR
Intervention: Standard oral levodopa/carbidopa administration
Number of subjects: 16
Study 38698643 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional palliative care intervention (TPC) for FCGs, involving teaching, guidance, and counseling via video calls for 8 weeks after CR discharge.
Number of subjects: 282
Study 38698643 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition for FCGs.
Number of subjects: 282
Study 38698643 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional palliative care intervention (TPC) for FCGs.
Number of subjects: 282
Study 38699307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib, Lenalidomide, and Dexamethasone (IRD)
Number of subjects: 55
Study 38699346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (duloxetine + web-based self-guided CBT) with phone-based motivational interviewing (MI)
Number of subjects: 280
Study 38699346 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment without phone-based MI
Number of subjects: 280
Study 38699346 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine monotherapy
Number of subjects: 280
Study 38699828 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and metronidazole
Number of subjects: 84
Study 38699828 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin and metronidazole
Number of subjects: 84
Study 38699828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 38699939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cedirogant 75 mg
Number of subjects: 156
Study 38699939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cedirogant 150 mg
Number of subjects: 156
Study 38699939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cedirogant 375 mg
Number of subjects: 156
Study 38699939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 38700040 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg QD
Number of subjects: 787
Study 38700040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study 38700045 — intervention group
Group type: COMPARATOR
Intervention: Antiviral medications (aciclovir, ganciclovir, valaciclovir)
Number of subjects: 5054
Study 38700045 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 5054
Study 38700045 — intervention group
Group type: COMPARATOR
Intervention: Extended duration prophylaxis
Number of subjects: 5054
Study 38700045 — intervention group
Group type: COMPARATOR
Intervention: Maribavir
Number of subjects: 5054
Study 38700322 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural sGFAP levels
Number of subjects: 38
Study 38700322 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 38
Study 38700322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower sGFAP levels
Number of subjects: 38
Study 38700322 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sNfL levels
Number of subjects: 38
Study 38700322 — intervention group
Group type: EXPERIMENTAL
Intervention: sNfL-to-sGFAP ratio
Number of subjects: 38
Study 38700557 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38700568 — intervention group
Group type: EXPERIMENTAL
Intervention: Preanesthesia teleconsultation
Number of subjects: 0
Study 38700568 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 38700579 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of rh-endostatin (210 mg) over a period of 120 hours combined with platinum-based doublet chemotherapy (pemetrexed or paclitaxel) in 21-day cycles.
Number of subjects: 48
Study 38700601 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular plugs (MVPs)
Number of subjects: 60
Study 38700601 — intervention group
Group type: COMPARATOR
Intervention: Platinum-fibered microcoils
Number of subjects: 60
Study 38700601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MVPs and coils
Number of subjects: 60
Study 38700630 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day bismuth-containing quadruple therapy
Number of subjects: 1300
Study 38700630 — intervention group
Group type: COMPARATOR
Intervention: 14-day bismuth-containing quadruple therapy
Number of subjects: 1300
Study 38700646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg as monotherapy every 2 weeks for 16 weeks
Number of subjects: 0
Study 38700646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg
Number of subjects: 0
Study 38700646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38700657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with new-onset atrial fibrillation (NOAF)
Number of subjects: 473
Study 38700657 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CURB-65, PSI class, and CHA score in NOAF patients
Number of subjects: 473
Study 38700656 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta variant infection
Number of subjects: 758
Study 38700656 — intervention group
Group type: COMPARATOR
Intervention: Omicron variant infection
Number of subjects: 758
Study 38700656 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient cohort
Number of subjects: 758
Study 38700708 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran Extended Release
Number of subjects: 0
Study 38700708 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38700808 — intervention group
Group type: EXPERIMENTAL
Intervention: Apitolisib (PI3K/mTOR inhibitor)
Number of subjects: 2
Study 38700867 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-supported, internet-delivered exposure and response prevention (ERP) for 10 weeks
Number of subjects: 221
Study 38700867 — intervention group
Group type: COMPARATOR
Intervention: Therapist-supported, internet-delivered psychoeducation for 10 weeks
Number of subjects: 221
Study 38700867 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic evaluation of ERP
Number of subjects: 221
Study 38700867 — intervention group
Group type: COMPARATOR
Intervention: Health economic evaluation of psychoeducation
Number of subjects: 221
Study 38700862 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin transfusion threshold
Number of subjects: 1690
Study 38700862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower hemoglobin transfusion threshold
Number of subjects: 1690
Study 38700862 — intervention group
Group type: COMPARATOR
Intervention: Control periods (pretransfusion periods)
Number of subjects: 1690
Study 38700928 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional social transfer at 6 months post partum
Number of subjects: 300
Study 38700928 — intervention group
Group type: EXPERIMENTAL
Intervention: Social transfer at 6 months post partum conditional upon mothers exclusively breastfeeding
Number of subjects: 300
Study 38700928 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials supporting mothers to exclusively breastfeed (provided to all groups)
Number of subjects: 300
Study 38700928 — intervention group
Group type: COMPARATOR
Intervention: Control group, no social transfer
Number of subjects: 300
Study 38701074 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention (#SafeHandsSafeHearts)
Number of subjects: 202
Study 38701088 — intervention group
Group type: EXPERIMENTAL
Intervention: YANG NIR spectroscopy sensor (Indigo) implanted for 28 days
Number of subjects: 7
Study 38701179 — intervention group
Group type: EXPERIMENTAL
Intervention: rSS = 0
Number of subjects: 408
Study 38701179 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 < rSS ≤ 8
Number of subjects: 408
Study 38701179 — intervention group
Group type: EXPERIMENTAL
Intervention: rSS > 8
Number of subjects: 408
Study 38701179 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual ischaemia (rSS)
Number of subjects: 408
Study 38701179 — intervention group
Group type: COMPARATOR
Intervention: Baseline SYNTAX score
Number of subjects: 408
Study 38701390 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance
Number of subjects: 435
Study 38701390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 435
Study 38701435 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 3923
Study 38701435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3923
Study 38701440 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management program (Agir pour moi - APM)
Number of subjects: 63
Study 38701490 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (home exercise, branched-chain amino acids, multistrain probiotic)
Number of subjects: 32
Study 38701490 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 32
Study 38701490 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 32
Study 38701812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (17.5 ± 2.5 mg/kg per day for 6 months, followed by dose escalation up to 20-35 mg/kg per day)
Number of subjects: 606
Study 38701812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea dose escalation to MTD with dose optimisation
Number of subjects: 606
Study 38701817 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 566
Study 38701817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 566
Study 38701817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study 38701823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 10259
Study 38701823 — intervention group
Group type: COMPARATOR
Intervention: No nirsevimab
Number of subjects: 10259
Study 38701878 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 43
Study 38701878 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 43
Study 38701878 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF
Number of subjects: 43
Study 38701878 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study 38701881 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawing neurohormonal blockers
Number of subjects: 0
Study 38701881 — intervention group
Group type: COMPARATOR
Intervention: Neurohormonal blockers (control group)
Number of subjects: 0
Study 38701961 — intervention group
Group type: EXPERIMENTAL
Intervention: Down Sizing Strategy (HANGZHOU Solution)
Number of subjects: 0
Study 38701961 — intervention group
Group type: COMPARATOR
Intervention: Standard Annulus Sizing Strategy
Number of subjects: 0
Study 38702085 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0
Study 38702085 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study 38702342 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/AA ratio in Group 4
Number of subjects: 180
Study 38702342 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Reactive Protein
Number of subjects: 180
Study 38702342 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 180
Study 38702523 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic and equitable digital-health-team-based care program implementing tighter glucose targets (HbA1c < 7%), early technology use (continuous glucose monitoring starts <1 month after diagnosis), remote patient monitoring
Number of subjects: 0
Study 38702523 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic and equitable digital-health-team-based care program
Number of subjects: 0
Study 38702618 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with fever (ERMF)
Number of subjects: 60
Study 38702618 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia without fever
Number of subjects: 60